Program
hMPV_Y low dose vaccine
Also written as “hMPV_Y medium dose vaccine”, “hMPV_Y high dose vaccine” and “hMPV_Z low dose vaccine”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 2since May 26, 2026 | May 26, 2026 | Apr 5, 2029phase 2 · NCT07628049 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2026First study: phase 2 study in Respiratory Syncytial Virus Infections+MetapneumovirusFirst studyNCT07628049 · 1,456 planned · United States, Australia
Ahead
- Apr 5, 2029Primary completion: phase 2 study in Respiratory Syncytial Virus Infections+MetapneumovirusNCT07628049
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“hMPV_Y low dose vaccine”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07628049Respiratory Syncytial Virus Infections+Metapneumovirus · United States, Australia | 2 | Recruiting | Apr 5, 2029 | 1,456 |
How it is read
Names in the registry
- “hMPV_Y low dose vaccine”, 1 entry
- “hMPV_Y medium dose vaccine”, 1 entry
- “hMPV_Y high dose vaccine”, 1 entry
- “hMPV_Z low dose vaccine”, 1 entry
- “hMPV_Z medium dose vaccine”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.